Evidence that the TM1-TM2 loop contributes to the rho1 GABA receptor pore

• Published in: The Journal of biological chemistry Vol. 279; no. 20; p. 20906
• Main Authors: Filippova, Natalia, Wotring, Virginia E, Weiss, David S
• Format: Journal Article
• Language: English
• Published: United States 14-05-2004
• Subjects: Amino Acid Sequence; Amino Acid Substitution; Animals; Binding Sites; Cadmium - pharmacology; Cysteine; Ethyl Methanesulfonate - analogs & derivatives; Ethyl Methanesulfonate - pharmacology; Female; gamma-Aminobutyric Acid - pharmacology; Membrane Potentials - drug effects; Molecular Sequence Data; Mutagenesis, Site-Directed; Oocytes - physiology; Polymerase Chain Reaction - methods; Receptors, GABA - chemistry; Receptors, GABA - drug effects; Receptors, GABA - genetics; Receptors, GABA - physiology; Recombinant Proteins - chemistry; Recombinant Proteins - drug effects; Recombinant Proteins - metabolism; Transfection; Xenopus laevis
• ISSN: 0021-9258

Considerable evidence indicates the second transmembrane domain (TM2) of the gamma-aminobutyric acid (GABA) receptor lines the integral ion pore. To further delineate the structures that constitute the ion pore and selectivity filter of the rho1 GABA receptor, we used the substituted cysteine accessibility method with charged reagents to identify anion- and cation-accessible surfaces. Twenty-one consecutive residues were mutated to cysteine, one at a time, in the presumed intracellular end of the first transmembrane domain (TM1; Ala(271)-Met(276)), the entire linker connecting TM1 to TM2 (Leu(277)-Arg(287)), and the presumed intracellular end of TM2 (Ala(288)-Ala(291)). Positively (MTSEA(+)) and negatively (pCMBS(-)) charged sulfhydryl reagents, as well as Cd(2+), were added extracellularly to test accessibility of the engineered cysteines. Four of the mutants, all at the intracellular end of TM2 (R287C, V289C, P290C, A291C), were accessible to positively charged reagents, whereas seven mutants (A271C, T272C, L277C, W279C, V280C, P290C, A291C) were functionally modified by negatively charged pCMBS(-). These seven modified residues were at the intracellular end of TM2, in the TM1-TM2 linker, and at the intracellular end of TM1. In nearly all cases (excluding P290C), the rate and the degree of modification were state-dependent, with greater accessibility in the presence of agonist. Select cysteine mutants were combined with a point mutation (A291E) that converted the pore from chloride- to non-selective. In this case, positively charged reagents could modify residues in the TM1-TM2 linker (Leu(277) and Val(280)), supporting the notion that the modifying reagents were reaching their target through the pore. Taken together, our results suggest that, up to its intracellular end, the TM2 domain is not charge selective. In addition, we propose that the TM1-TM2 linker and the intracellular end of TM1 are along the pathway of the permeating ion. These findings may lend new insights into the structure of the GABA receptor pore.